Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme

British Journal of Pharmacology

Volumn 149, Issue 6, 2006, Pages 775-785

  Freeman, S ^a   Bartlett, J B ^a   Convey, G ^a   Hardern, I ^a   Teague, J L ^a   Loxham, S J G ^a   Allen, J M ^a   Poucher, S M ^a   Charles, A D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

1,4 dideoxy 1,4 imino D arabinitol; AMP; Caffeine; Glucose; Glycogen; GPi688; GPi819; Liver phosphorylase; Skeletal muscle phosphorylase; Zucker fa fa

Indexed keywords

2 CHLORO N [1 (2,3 DIHYDROXYPROPYL) 2 OXO 1,2,3,4 TETRAHYDROQUINOLIN 3 YL] 6H THIENO[2,3 B]PYRROLE 5 CARBOXAMIDE; CAFFEINE; ENZYME INHIBITOR; GLUCOSE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE INHIBITOR; GPI 688; GPI 819; N [1 BENZYL 2 HYDROXY 3 [METHOXY(METHYL)AMINO] 3 OXOPROPYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SOLEUS MUSCLE; STEADY STATE;

ANIMALS; CAFFEINE; ENZYME ACTIVATION; ENZYME INHIBITORS; GLYCOGEN PHOSPHORYLASE; INDOLES; ISOENZYMES; MUSCLE, SKELETAL; RATS; RATS, ZUCKER; RECOMBINANT PROTEINS;

EID: 33751001756     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706925     Document Type: Article

References (42)

1. Arabadjis PG, Tullson PC, Terjung RL (1993). Purine nucleoside formation in rat skeletal muscle fiber types. Am J Physiol Cell Physiol 264: C1246-C1251.
2. AstraZeneca (2003). Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase. World Intellectual Property Organisation WO 03/074532 A1.
3. Baker DJ, Timmons JA, Greenhaff PL (2005). Glycogen phosphorylase inhibition in type 2 diabetes therapy. A systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 54: 2453-2459.
4. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Buchbinder JL, Rath VL, Fletterick RJ (2001). Structural relationships among regulated and unregulated phosphorylases. Annu Rev Biophy Biomol Struct 30: 191-209.
6. 13C NMR method to assess intracellular glucose concentration inmuscle, in vivo. Am J Physiol Endocrinol Metab 274: E381-E389.
7. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z et al. (1999). Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341: 240-246.
8. Ercan N, Gannon MC, Nuttall FQ (1996). Allosteric regulation of liver phosphorylase a: revisited under approximated physiological conditions. Arch Biochem Biophys 328: 255-264.
9. Ercan-Fang N, Gannon MC, Rath VL, Treadway JL, Taylor MR, Nuttall FQ (2002). Integrated effects of multiple modulators on human liver glycogen phosphorylase a. Am J Physiol Endocrinol Metab 283: E29-E37.
10. Fosgerau K, Westergaard N, Quistorff B, Grunnet N, Kristiansen M, Lundgren K (2000). Kinetic and functional characterization of 1,4-dideoxy-1,4-imino-D-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice. Arch Biochem Biophys 380: 274-284.
11. Hancock CR, Janssen E, Terjung RL (2005). Skeletal muscle contractile performance and ADP accumulation in adenylate kinase-deficient mice. Am J Physiol Cell Physiol 288: C1287-C1297.
12. Hancock CR, Janssen E, Terjung RL (2006). Contraction-mediated phosphorylation of AMPK is lower in skeletal muscle of adenylate kinase-deficient mice. J Appl Physiol 100: 406-413.
13. 31P-N.M.R. spectroscopy, and its implications for metabolic control. Biochem J 229: 141-151.
14. Johnson LN (1992). Glycogen phosphorylase: control by phosphorylation and allosteric effectors. FASEB J 6: 2274-2282.
15. Kasvinsky PJ, Shechosky S, Fletterick RJ (1978). Synergistic regulation of phosphorylase a by glucose and caffeine. J Biol Chem 253: 9102-9106.
16. Kobayashi M, Soman G, Graves DJ (1982). A comparison of the activator sites of liver and muscle glycogen phosphorylase b. J Biol Chem 257: 14041-14047.
17. Koch JE, Ji H, Osbakken MD, Friedman MI (1998). Temporal relationships between eating behavior and liver adenine nucleotides in rats treated with 2,5-AM. Am J Physiol Regul Integr Comp Physiol 274: R610-R617.
18. 13C-NMR spectroscopy. Magn Reson Med 44: 556-562.
19. Lerin C, Montell E, Nolasco T, Garcia-Rocha M, Guinovart JJ, Gomez-Foix A M (2004). Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. Biochem J 378: 1073-1077.
20. Lowry OH, Schulz DW, Passonneau JV (1964). Effects of adenylic acid on the kinetics of muscle phosphorylase a. J Biol Chem 239: 1947-1953.
21. Lowry OH, Schulz DW, Passonneau JV (1967). The kinetics of glycogen phosphorylases from brain and muscle. J Biol Chem 242: 271-280.
22. Lukacs CM, Oikonomakos NG, Crowther RL, Hong L, Kammlott RU, Levin W et al. (2006). The crystal structure of human muscle glycogen phosphorylase a with bound glucose and AMP: an intermediate conformation with T-state and R-state features. Proteins 63: 1123-1126.
23. Luong CBH, Browner MF, Fletteric RJ, Haymore BL (1992). Purification of glycogen phosphorylase isozymes by metal-affinity chromatography. J Chromatogr Biomed Appl 584: 77-84.
24. Maddaiah VT, Madsen NB (1966). Kinetics of purified liver phosphorylase. J Biol Chem 241: 3873-3881.
25. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE et al. (1998). Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci USA 95: 1776-1781.
26. McCormack JG, Westergaard N, Kristiansen M, Brand CL, Lau J (2001). Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr Pharm Des 7: 1451-1474.
27. Newgard CB, Hwang PK, Fletterick RJ (1989). The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 24: 69-99.
28. Newsholme EA, Leech AR (eds.) (1983). Metabolism in exercise. In: Biochemistry for the Medical Sciences. Wiley: Chichester, pp. 357-381.
29. Oikonomakos NG, Acharya KR, Johnson LN (1992). Rabbit muscle glycogen phosphorylase b. The structural basis of activation and catalysis. In: Harding JJ, Crabbe MJC (eds.) Post-Translational Modifications of Proteins. CRC Press: Roca Raton, pp 81-151.
30. Oikonomakos NG, Chrysina ED, Kosmopoulou MN, Leonidas DD (2003). Crystal structure of rabbit muscle glycogen phophorylase a in complex with a potential hypoglycaemic drug at 2.0 angstrom resolution. Biochim Biophys Acta 1647: 325-332.
31. Oikonomakos NG, Skamnaki VT, Tsitsanou KE, Gavalas NG, Johnson LN (2000). A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure 8: 575-584.
32. Oikonomakos NG, Zographos SE, Skamnaki VT, Archontis G (2002). The 1.76 angstrom resolution crystal structure of glycogen phosphorylase B complexed with glucose, and CP320626, a potential antidiabetic drug. Bioorg Med Chem 10: 1313-1319.
33. Pfizer Inc. (1995). Substituted N-(Indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors. World Intellectual Property Organisation WO 96/39385 A1.
34. Rath VL, Ammirati M, Danley DE, Ekstrom JL, Gibbs EM, Hynes TR et al. (2000a). Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem Biol 7: 677-682.
35. Rath VL, Ammirati M, LeMotte PK, Fennell KF, Mansour MN, Danley DE et al. (2000b). Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Mol Cell 6: 139-148.
36. Rowland M, Tozer TN (1995). Physiologic Concepts and Kinetics. Distribution. In: Balado D (ed.) Clinical Pharmacokinetics, Concepts and Applications. Lippincott Williams & Wilkins: Philadelphia, pp 137-155.
37. Rush JWE, Spriet LL (2001). Skeletal muscle glycogen phosphorylase a kinetics: effects of adenine nucleotides and caffeine. J Appl Physiol 91: 2071-2078.
38. Sprang SR, Withers SG, Goldsmith EJ, Fletterick RJ, Madsen NB (1991). Structural basis for the activation of glycogen phosphorylase b by adenosine monophosphate. Science 254: 1367-1371.
39. Stalmans W, Gevers G (1981). The catalytic activity of phosphorylase b in the liver. Biochem J 200: 327-336.
40. Stalmans W, Laloux M, Hers H-G (1974). The interaction of liver phosphorylase a with glucose and AMP. Eur J Biochem 49: 415-427.
41. Tan AWH, Nuttall FQ (1975). Characteristics of the dephosphorylated form of phosphorylase purified from rat liver and measurement of its activity in crude liver preparations. Biochim et Biophys Acta 410: 45-60.
42. Wheeler TJ, Lowenstein JM (1979). Adenylate deaminase from rat muscle. J Biol Chem 254: 8994-8999.